Cytotoxic Drugs and Hormonal Manipulations in the Management of Carcinoma of the Kidney

  • A. S. D. Spiers
Part of the Clinical Practice in Urology book series (PRACTICE UROLOG)


The commonest renal tumor in adults is that arising from the cells of renal parenchyma. These cancers were described by Grawitz (1883), who named them hypernephromas upon the supposition that they might arise from nests of adrenal tissue in the kidney. The names ‘hypernephroma’ and ‘Grawitz tumor’ are obsolete, and renal carcinoma (or renal cell carcinoma) is the most appropriate term, since the tumors arise from the secretory cells of the renal tubular epithelium. Renal carcinoma is not a common disease; its incidence is about 7.5 cases per 100,000 population. In the United States there are about 7000 deaths from this tumor each year (American Cancer Society 1973): this represents 2.3% of male cancer deaths and 1.6% of cancer deaths in women.


Testosterone Cyclophosphamide Vincristine Adriamycin Melamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alberto P, Senn HJ (1974) Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs. Cancer 33:1226–1229PubMedCrossRefGoogle Scholar
  2. Al-Sarraf M (1979) The clinical trial of tamoxifen in patients with advanced renal cell cancer. A Southwest Oncology Group study. Proc Am Soc Clin Oncol 20:378, C-360Google Scholar
  3. American Cancer Society (1973) Cancer facts and figures. New York: American Cancer SocietyGoogle Scholar
  4. Bloom HJG (1973) Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer 32: 1066–1071PubMedCrossRefGoogle Scholar
  5. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410PubMedCrossRefGoogle Scholar
  6. Bukowski RM, Groppe C, Reimer R, Weick J, Hewlett JS (1979) Immunotherapy (IT)of metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 20:402, C-457Google Scholar
  7. Carter RL (1968) The pathology of renal cancer. JAMA 204:221–222PubMedCrossRefGoogle Scholar
  8. Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36:729–747PubMedCrossRefGoogle Scholar
  9. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 310:592–595CrossRefGoogle Scholar
  10. Concolino G, Marocchi A, Conti C, Tenaglia R, Di Silverio F, Bracci U (1978) Human renal cell carcinoma as a hormone-dependent tumor. Cancer Res 38:4340–4344PubMedGoogle Scholar
  11. Currie VE, Kempin SJ, Sykes MP, Young CW (1979) Clinical studies of 2,4-diamino-5-(3’4’-dichlorophenyl)-6-methylpyrimidine (metoprine) with and without leucovorin. Proc Am Assoc Cancer Res 20:112,454Google Scholar
  12. Davis TE, Manalo FB (1978) Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine. Proc Am Soc Clin Oncol 19:316, C-39Google Scholar
  13. Everson TC, Cole WH (1966) Spontaneous regression of cancer. Saunders, Philadelphia LondonGoogle Scholar
  14. Faulconer RJ, Rosato FE, Wright GL, Schellhammer P (1978) Detection and isolation of antigens associated with renal cell carcinoma. Proc Am Soc Clin Oncol 19:308, C-8Google Scholar
  15. Fuks JZ, Van Echo DA, Aisner J, Kravitz S, Wiernik PH (1980) A Phase II trial of 4’-(9-acrindinyl-amino)-methanesulfon-m-anisidine (AMSA) in patients with renal cell carcinoma (RCC) and refractory small cell carcinoma of the lung (SCCL). Proc Am Soc Clin Oncol 21:477, C-622Google Scholar
  16. Ghose T, Tai J, Blair AH, Belitsky P, Aquino J, Norvell ST (1978) Antitumor antibodies as carriers of radionucleidesand cytotoxic drugs. Proc Am Assoc Cancer Res 19:236,942Google Scholar
  17. Glick J, Wein A, Negendank W, Harris D, Brodovsky H, Padavic K, Torri S (1979) Tamoxifen in metastatic prostate and renal cancer. Proc Am Soc Clin Oncol 20:311, C-81Google Scholar
  18. Grawitz P (1883) Die sogenannten Lipomas der Niere. Virchow Arch [Pathol Anat] 93:39–63CrossRefGoogle Scholar
  19. Hahn RG (1977) Megace, VP-16, Cytoxan and galactitol. Phase II treatment trials in advanced renal cell cancer. Proc Am Soc Clin Oncol 18:332, C-262Google Scholar
  20. Hahn RG, Temkin NR, Savlov ED, Perlia C, Wampler GL, Horton J, Marsh J, Carbone PP (1978) Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep 62:1093–1095PubMedGoogle Scholar
  21. Hrushesky WJ (1977) What’s old and new in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 18: 318, C-206Google Scholar
  22. Ishmael DR, Bottomley R, Geyer J (1980) Effect of nephrectomy on eventual response to chemotherapy in renal cell carcinoma. Proc Am Soc Clin Oncol 21:429, C-439Google Scholar
  23. Ishmael DR, Bottomley RH, Hoge AF (1976) Treatment of renal cell adenocarcinoma (hypernephroma) with Depo-Provera and combination chemoimmunotherapy. Proc Am Soc Clin Oncol 17:265, C-113Google Scholar
  24. Ishmael DR, Burpo LJ, Bottomley RH (1978) Combined therapy of advanced hypernephroma with medroxyprogesterone, BCG, adriamycin and vincristine. Proc Am Soc Clin Oncol 19:407, C-403Google Scholar
  25. Katakkar SB, Franks CR (1978) Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate. Cancer Treat Rep 62: 1379–1380PubMedGoogle Scholar
  26. Kato T, Nemoto R, Mori H, Kumagai I (1979) Microencapsulated mitomycin-C therapy in renal cell carcinoma. Lancet II: 479–480CrossRefGoogle Scholar
  27. Kirkman H (1959) Estrogen-induced tumors of the kidney in the Syrian hamster. Natl Cancer Inst Mongr 1: 1–37Google Scholar
  28. Kirulata G, Morales A, Lott S (1975) Response of renal adenocarcinoma to cyclophosphamide. Urology 6: 557–558CrossRefGoogle Scholar
  29. Knight WA, Livingston RB, Fabian C, Costanzi J (1979) Methyl-glyoxal bis-guanylhydrazone (methyl-GAG, MGBG) in advanced human malignancy. Proc Am Soc Clin Oncol 20:319, C-115Google Scholar
  30. Knight WA, Livingston RB, Fabian C, Costanzi J (1980) Methyl-glyoxal bis-guanulhydrazone (methyl-GAG, MGBG) in advanced renal carcinoma. Proc Am Soc Clin Oncol 21: 367, C-190Google Scholar
  31. Kradjian JM, Bennington JL (1964) Renal carcinoma recurrent 31 years after nephrectomy. Arch Surg 90:192–195Google Scholar
  32. Levi J A, Dalley D, Aroney R (1980) A comparative trial of the combination vinblastine (V), methotrexate (A) and bleomycin (B) with and without tamoxifen (T) for metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 21:426, C-425Google Scholar
  33. Li JJ, Li SA, Gonzales R(1979) Specific hormone binding in human renal carcinoma and kidney. Proc Am Assoc Cancer Res 20: 273, 1107Google Scholar
  34. Lokich JL, Harrison JH (1975) Renal cell carcinoma: natural history and chemotherapeutic experience. J Urol 114: 371–374PubMedGoogle Scholar
  35. Luderer RC, Opipari MI, Perrotta AL (1978) Treatment of metastatic renal cell carcinoma: Review of experience and world literature. Journal of the American Osteopathic Association 77: 590–603PubMedGoogle Scholar
  36. McPherson TA, Tan YH (1979) Phase I study of human fibroblast interferon (FI) in human malignancy. Proc Am Soc Clin Oncol 20:378, C-361Google Scholar
  37. Middleton RG (1967) Surgery for metastatic renal cell carcinoma. J Urol 97:973–977PubMedGoogle Scholar
  38. Miller CF, Blom J (1980) Adjuvant chemotherapy of renal cell carcinoma using a combination of bleomycin (BLM) and lomustine (CCNU). Proc Am Soc Clin Oncol 21:362, C-171Google Scholar
  39. Mittelman A, Albert DJ, Murphy GP (1973) Lomustine treatment of metastatic renal cell carcinoma. JAMA 225: 32–35PubMedCrossRefGoogle Scholar
  40. Papac R, Luikhart S, Kirkwood J (1980) High-dose tamoxifen in patients with advanced renal cell cancer and malignant melanoma. Proc Am Soc Clin Oncol 21: 358, C-155Google Scholar
  41. Papac RJ, Ross AS, Levy A (1977) Renal cell carcinoma: analysis of 31 cases with assessment of endocrine therapy. Am J Med Sci 274: 281–289PubMedCrossRefGoogle Scholar
  42. Prager MD, Peters PC, Baechtel FS, Brown G (1980) Specific immunotherapy of metastatic human renal cell carcinoma: preliminary results. Proc Am Assoc Cancer Res 21:213,856Google Scholar
  43. Price LA, Goldie JH, Hill BT (1975) Methodichlorophen as anti-tumour drug. Br Med J i: 20–21CrossRefGoogle Scholar
  44. Prout GR (1973) The kidney and ureter. In: Holland JF, Frei E (eds) Cancer medicine. Lea & Febiger, Philadelphia, pp 1655–1669Google Scholar
  45. Ramming KP, deKernion JB (1977) Immune RNA therapy for renal cell carcinoma: Survival and immunologic monitoring. Ann Surg 186:459–466PubMedCrossRefGoogle Scholar
  46. Ramming KP, Gupta RK, deKernion JB (1977) Detection of antibodies to tumor associated antigens in patients with hypernephroma. Proc Amer Soc Clin Oncol 18:319, C-211Google Scholar
  47. Ramming KP, Gupta RK, deKernion JB (1979) Induction of antibody to human renal cell cancer in vivo by injections of xenogeneic immune RNA. Proc Am Assoc Cancer Res 20:215, 872Google Scholar
  48. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297–301PubMedGoogle Scholar
  49. Rodriguez LH, Johnson DE (1978) Clinical trial of cisplatinum (NSC 119875) in metastatic renal cell carcinoma. Urology 11:344–346PubMedCrossRefGoogle Scholar
  50. Samuels ML, Sullivan P, Howe CD (1968) Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma). Cancer 22:525–532PubMedCrossRefGoogle Scholar
  51. Spiers ASD, Allar M (1979) Beneficial effects of concurrent androgen treatment during cytotoxic chemotherapy. Proc Am Soc Clin Oncol 20:295, C-8Google Scholar
  52. Talley RW (1973) Chemotherapy of adenocarcinoma of the kidney. Cancer 32: 1062–1065PubMedCrossRefGoogle Scholar
  53. Todd RF, Garnick MB, Canellos GP (1980) Chemotherapy of advanced renal adenocarcinoma with methyl-glyoxal-bis-guanylhydrazone (methyl-GAG). Proc Am Soc Clin Oncol 21:340, C-85Google Scholar
  54. Wagle DG, Murphy GP (1971) Hormonal therapy in advanced renal cell carcinoma. Cancer 28:318–321PubMedCrossRefGoogle Scholar
  55. Wajsman Z, Beckley S, Madajewucz S, Dragone N (1980) High-dose cyclophosphamide (CPM) in metastatic renal cell cancer. Proc Am Soc Clin Oncol 21: 423, C-413Google Scholar
  56. Woodruff MW, Wagle D, Gailani SD, Jones R (1967) The current status of chemotherapy for advanced renal carcinoma. J Urol 97: 611–618PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • A. S. D. Spiers

There are no affiliations available

Personalised recommendations